Raymond James downgrades BridgeBio Pharma stock rating on payer risks

Raymond James downgraded BridgeBio Pharma to Market Perform from Outperform, citing rising payer-driven risk as Vyndamax loss of exclusivity approaches in 2031. The firm cut its 2035 Attruby estimate to $1.7 billion from $2.1 billion and warned that new patient starts may become harder beyond 2031 as generic Vyndamax is likely prioritized. Offset by strong Q1 2026 results, BridgeBio reported revenue of $194.5 million, beating the $178.16 million consensus by 9.18%, while EPS of -$0.84 missed expectations.

Analysis

This downgrade is less about near-term execution and more about the terminal value of the franchise being compressed by payer behavior. In crowded rare-disease categories, the first durable share loss usually comes not from clinical inferiority but from formulary normalization: once a lower-cost option establishes a reimbursement precedent, later entrants get forced into narrower access or step edits even if physicians prefer them. That dynamic matters here because the market is already paying for multiple years of high growth, leaving little margin for even modest haircut risk in the 2030-2035 window.

The second-order issue is that combination therapy can paradoxically cap the upside of the very asset that creates it. If TTR silencers become the standard add-on, the market may shift from a differentiated monotherapy expansion story to a lower-price bundle story, which lowers per-patient economics and reduces switching optionality. That tends to rerate the whole franchise from “category creator” to “one component in a managed-care regimen,” and multiples usually compress before revenue does.

Near term, the catalyst set is still supportive, but the stock’s asymmetric setup is weakening: positive pipeline news and revenue beats can keep the name elevated, yet each beat now likely gets sold into because long-duration expectations are doing more work than quarterly fundamentals. The key risk is that consensus is anchoring on peak-sales narratives while underestimating how quickly payer scrutiny can intensify once the incumbent’s exclusivity clock becomes visible. If that happens, growth can remain strong for years while the stock underperforms because the market discounts the last leg of the curve.

Key Decisions for Investors

• Trim BBIO into strength on any post-news rally; use a 1-3 month horizon and treat $70+ as a zone where upside looks increasingly dependent on multiple expansion rather than fundamentals.
• Initiate a BBIO / large-cap profitable biotech pair trade: long a cash-generative biotech with stable reimbursement exposure, short BBIO, to isolate payer/LOE multiple compression over the next 6-12 months.
• Buy medium-dated BBIO puts or put spreads if implied volatility is reasonable; the risk/reward favors downside protection against a rerating event before the 2026-2027 pipeline visibility improves.
• If holding BBIO long-term, hedge with a partial short against the basket of high-multiple biotech names; the idea is to keep pipeline exposure while reducing valuation risk tied to payer scrutiny.